Skip to main content
. 2022 Feb;10(3):139. doi: 10.21037/atm-21-6608

Figure 2.

Figure 2

METTL3 is correlated with poor OS in NSCLC patients. (A,B) Quantification of METTL3 mRNA and protein expression in chemoresistant and chemosensitive NSCLC tissues; (C,D) the relationship between METTL3 expression and OS of NSCLC patients was analyzed using Kaplan-Meier survival curves. ****P<0.0001. METTL3, methyltransferase-like 3; OS, overall survival; NSCLC, non-small cell lung cancer.